SCHEMBL19475453

SCHEMBL19475453

CC(=O)Nc1ccc(-c2cc(CO)c3ccccc3n2)cc1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MOK Q9UQ07 13/20 0.77
KMT2A Q03164 5/20 0.73
KDM4E B2RXH2 3/20 0.73
PDE10A Q9Y233 1/20 0.73
MEN1 O00255 4/20 0.68
ALDH1A1 P00352 4/20 0.68
MAPT P10636 2/20 0.63
HPGD P15428 2/20 0.63
NPSR1 Q6W5P4 1/20 0.63
RXFP1 Q9HBX9 1/20 0.63
CYP2C19 P33261 1/20 0.63
TP53 P04637 1/20 0.61
CYP1A2 P05177 1/20 0.61
HSD17B10 Q99714 1/20 0.61
ABCB1 P08183 1/20 0.59
ABCC1 P33527 1/20 0.59
ABCG2 Q9UNQ0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19475327 0.90 MOK (0.70) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475373 0.89 MOK (0.72) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475379 0.87 MOK (1.00) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475403 0.86 MOK (0.65) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475445 0.85 MOK (0.84) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475299 0.85 KMT2A (0.65) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475460 0.85 MOK (1.00) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL5154506 0.84 KDM4E (1.00) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475498 0.84 KMT2A (0.85) MOKKMT2AKDM4EPDE10AMEN1
SCHEMBL19475602 0.84 MOK (1.00) MOKKMT2AKDM4EPDE10AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof UNIV NEW YORK (US) 2021-12-07 US disclosed
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof UNIV NEW YORK (US) 2021-12-07 US disclosed
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF UNIV NEW YORK (US) 2019-06-27 US disclosed
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF UNIV NEW YORK (US) 2019-06-27 US disclosed
WO-2017184547-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF NEW YORK UNIVERSITY (US) 2017-10-26 WO disclosed
WO-2017184547-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF NEW YORK UNIVERSITY (US) 2017-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF AGER, HMGB1, GPR119 MOK 4420/4885KMT2A 3436/4885KDM4E 2758/4885
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof AGER, HMGB1, GPR119 MOK 4420/4885KMT2A 3436/4885KDM4E 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.